170 related articles for article (PubMed ID: 36638143)
1. Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas.
Chen J; Wang Z; Phuc T; Xu Z; Yang D; Chen Z; Lin Z; Kendrick S; Dai L; Li HY; Qin Z
PLoS Pathog; 2023 Jan; 19(1):e1011089. PubMed ID: 36638143
[TBL] [Abstract][Full Text] [Related]
2. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
mBio; 2018 May; 9(3):. PubMed ID: 29739902
[TBL] [Abstract][Full Text] [Related]
3. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
Zhou F; Shimoda M; Olney L; Lyu Y; Tran K; Jiang G; Nakano K; Davis RR; Tepper CG; Maverakis E; Campbell M; Li Y; Dandekar S; Izumiya Y
Mol Cancer Ther; 2017 Nov; 16(11):2627-2638. PubMed ID: 28847988
[TBL] [Abstract][Full Text] [Related]
5. SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
Yeh WW; Chen YQ; Yang WS; Hong YC; Kao S; Liu TT; Chen TW; Chang L; Chang PC
J Virol; 2022 Aug; 96(16):e0075522. PubMed ID: 35914074
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
7. Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.
Gjyshi O; Roy A; Dutta S; Veettil MV; Dutta D; Chandran B
J Virol; 2015 Aug; 89(15):7874-92. PubMed ID: 25995248
[TBL] [Abstract][Full Text] [Related]
8. Developing new ceramide analogs and identifying novel sphingolipid-controlled genes against a virus-associated lymphoma.
Chen J; Goyal N; Dai L; Lin Z; Del Valle L; Zabaleta J; Liu J; Post SR; Foroozesh M; Qin Z
Blood; 2020 Nov; 136(19):2175-2187. PubMed ID: 32518949
[TBL] [Abstract][Full Text] [Related]
9. Effects of the NEDD8-Activating Enzyme Inhibitor MLN4924 on Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus.
Chang PJ; Chen LW; Chen LY; Hung CH; Shih YJ; Wang SS
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701396
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of KAP1 enhances hypoxia-induced Kaposi's sarcoma-associated herpesvirus reactivation through RBP-Jκ.
Zhang L; Zhu C; Guo Y; Wei F; Lu J; Qin J; Banerjee S; Wang J; Shang H; Verma SC; Yuan Z; Robertson ES; Cai Q
J Virol; 2014 Jun; 88(12):6873-84. PubMed ID: 24696491
[TBL] [Abstract][Full Text] [Related]
11. Expression and Subcellular Localization of the Kaposi's Sarcoma-Associated Herpesvirus K15P Protein during Latency and Lytic Reactivation in Primary Effusion Lymphoma Cells.
Smith CG; Kharkwal H; Wilson DW
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835496
[TBL] [Abstract][Full Text] [Related]
12. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
Saji C; Higashi C; Niinaka Y; Yamada K; Noguchi K; Fujimuro M
Biochem Biophys Res Commun; 2011 Dec; 415(4):573-8. PubMed ID: 22074820
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
Sarek G; Kurki S; Enbäck J; Iotzova G; Haas J; Laakkonen P; Laiho M; Ojala PM
J Clin Invest; 2007 Apr; 117(4):1019-28. PubMed ID: 17364023
[TBL] [Abstract][Full Text] [Related]
15. Regulation of KSHV Latency and Lytic Reactivation.
Broussard G; Damania B
Viruses; 2020 Sep; 12(9):. PubMed ID: 32957532
[TBL] [Abstract][Full Text] [Related]
16. Sirtuin 6 Attenuates Kaposi's Sarcoma-Associated Herpesvirus Reactivation by Suppressing Ori-Lyt Activity and Expression of RTA.
Hu M; Armstrong N; Seto E; Li W; Zhu F; Wang PC; Tang Q
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651359
[TBL] [Abstract][Full Text] [Related]
17. Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells.
Long C; Guo W; Zhou H; Wang J; Wang H; Sun X
Int J Oncol; 2016 Apr; 48(4):1519-30. PubMed ID: 26821279
[TBL] [Abstract][Full Text] [Related]
18. Activation of Kaposi's sarcoma-associated herpesvirus (KSHV) by inhibitors of class III histone deacetylases: identification of sirtuin 1 as a regulator of the KSHV life cycle.
Li Q; He M; Zhou F; Ye F; Gao SJ
J Virol; 2014 Jun; 88(11):6355-67. PubMed ID: 24672028
[TBL] [Abstract][Full Text] [Related]
19. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Ye J; Gradoville L; Daigle D; Miller G
J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
[TBL] [Abstract][Full Text] [Related]
20. The ORF45 Protein of Kaposi Sarcoma-Associated Herpesvirus Is an Inhibitor of p53 Signaling during Viral Reactivation.
Alzhanova D; Meyo JO; Juarez A; Dittmer DP
J Virol; 2021 Nov; 95(23):e0145921. PubMed ID: 34523970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
